Pharmacokinetics of abecarnil in patients with renal insufficiency

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 5, 1996, Pages 520-528

  Karara, Adel H ^a   Frye, Reginald F ^b   Hayes, Peggy E ^b   Weaver, Margaret L ^b   Robinson, William T ^b   Rault, Raymond M ^b   Matzke, Gary R ^b  

^a Sandoz Pharma Ltd   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABECARNIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; FEMALE; HEADACHE; HUMAN; KIDNEY FAILURE; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTI-ANXIETY AGENTS; BLOOD PROTEINS; CARBOLINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROTEIN BINDING; REGRESSION ANALYSIS;

EID: 0029892943     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90180-0     Document Type: Article

References (23)

1. Barestrup C, Nielsen M, Olsen CE. Urinary and brain β-carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors. Proc Natl Acad Sci USA 1980;77:2288-92.
2. Stephens DN, Schneider HH, Kehr W, et al. Abecarnil, a metabolically stable and selective β carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther 1990;253:334-43.
3. Turski L, Stephens DN, Jensen LH, et al. Anticonvulsant action of the β carboline abecarnil-studies in rodent and baboon. J Pharmacol Exp Ther 1990;253:344-52.
4. Ballenger JC, McDonald S, Noyes R, et al. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder. Psychopharmacol Bull 1991;27:171-9.
5. Krause W, Duka T, Matthes H. Pharmacokinetics and biotransformation of the anxiolytic abecarnil in healthy volunteers. Xenobiotica 1991;21:763-74.
6. Duka T, Schutt B, Krause W, Dorow R, McDonald S, Fichte K. Human studies on abecarnil a new β-carboline anxiolytic: safety, tolerability and preliminary pharmacological profile. Br J Clin Pharmacol 1993;35:386-94.
7. Krause W, Schütt B, Duka T. Pharmacokinetics and acute toleration of the β-carboline derivative abecarnil in man. Arzeimittelforschung 1990;40:529-32.
8. Matzke GR, Millikin SP. Influence of renal function and dialysis on drug disposition. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver: Applied Therapeutics, 1992;8:1-49.
9. Zini R, Riant P, Barre J, Tillement JP. Disease-induced variations in plasma protein levels: implications for drug dosage regimens; part I. Clin Pharmacokinet 1990;19:147-59.
10. Zini R, Riant P, Barre J, Tillement JP. Disease-induced variations in plasma protein levels: implications for drug dosage regimens; part II. Clin Pharmacokinet 1990;19:218-29.
11. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. Drug Intell Clin Pharm 1991;25:1214-24.
12. Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. Br J Anaesth 1993;71:282-90.
13. Karara AH, Filipek RW. Validation of an HPLC method for analysis of the novel anxiolytic abecarnil in plasma [Abstract]. Pharm Res 1991;8:S23.
14. Krause W, Mengel H, Nordholm L. Determination of β-carboline derivatives in biological samples by high performance liquid chromatography with fluorescence detection. J Pharm Sci 1989;78:622-6.
15. Akaike H. An information criterion (AIC). Math Sci 1976;14:5-9.
16. Yamoaka K, Nakagawa T, Uno T. Application of Akaike's criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-75.
17. Malagelada JR, Robertson JS, Brown ML, et al. Intestinal transit of solid and liquid components of a meal in health. Gastroenterology 1984;87:1255-63.
18. Reidenberg MM, Drayer DE, Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984;9:18-26.
19. Pritchard JF, Matzke GR, Opsahl JA, Halstenson CE, Nayak RK. Effects of hemodialysis on plasma protein binding of bepridil. J Clin Pharmacol 1995;35:137-41.
20. Haughey DB, Kraft CJ, Matzke GR, Keane WF, Halstenson CE. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol 1985;5:35-9.
21. Bilancioni DD, Pistocchi R, Mosconi E, et al. Serum alpha-1-acid glycoprotein in chronic renal failure. Nephron 1985;39:160.
22. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia: Lea & Febiger, 1989:179.
23. McNamara PJ, Gibaldi M, Stoeckel K. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding; II: physiological significance. Eur J Clin Pharmacol 1993;25: 407-12.